-
Something wrong with this record ?
A comprehensive quality control and cost comparison study of branded and generic angiotensin receptor blockers
AK. Sharma, S. Rastogi, F. Ali, AP. Yadav, RK. Goyal
Status not-indexed Language English Country Saudi Arabia
Document type Journal Article
NLK
Directory of Open Access Journals
from 2009
Free Medical Journals
from 2009
PubMed Central
from 2009
Europe PubMed Central
from 2009
Open Access Digital Library
from 2009-01-01
Open Access Digital Library
from 2009-07-01
ROAD: Directory of Open Access Scholarly Resources
- Publication type
- Journal Article MeSH
This study was designed to assess both the quality and cost aspects of various branded and generic formulations of angiotensin receptor blockers, specifically Irbesartan, Losartan Potassium, Olmesartan Medoxomil, Telmisartan, and Valsartan. The collected samples underwent distinct quality evaluations using the methods outlined in different global Pharmacopoeias (British Pharmacopoeia/European Pharmacopoeia, Indian Pharmacopoeia and United States Pharmacopoeia). These drugs were characterized using Fourier-Transform Infrared Spectroscopy and Nuclear Magnetic Resonance techniques, while their quality and concentration were analysed using High Performance Liquid Chromatography. The release profile of the drugs was examined through dissolution testing. Additionally, a cost comparison analysis was carried out by determining the prevailing market prices of the drugs. The evaluated branded and generic angiotensin receptor blockers were found to meet the established standards for impurities, active drug content, and dissolution as set by these Pharmacopoeias, indicating their optimal quality. Notably, the generic drugs exhibited significantly lower costs compared to their branded counterparts. This study confirms that the quality of generic angiotensin receptor blockers is equivalent to that of their branded counterparts. Consequently, these findings support the practicality of utilizing generic drugs as a more economically sustainable and cost-effective approach to managing diseases, especially those of chronic nature.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24005678
- 003
- CZ-PrNML
- 005
- 20240412130944.0
- 007
- ta
- 008
- 240405s2024 su f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.jsps.2024.101985 $2 doi
- 035 __
- $a (PubMed)38380162
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a su
- 100 1_
- $a Sharma, Arvind Kumar $u Delhi Pharmaceutical Science and Research University (DPSRU), Mehrauli-Badarpur Road, Sector-3, Pushp Vihar, New Delhi, 110017, India $u Indian Pharmacopoeia Commission, Ministry of Health and Family Welfare, Government of India, Sector-23 Raj Nagar, Ghaziabad, Uttar Pradesh, 201002, India
- 245 12
- $a A comprehensive quality control and cost comparison study of branded and generic angiotensin receptor blockers / $c AK. Sharma, S. Rastogi, F. Ali, AP. Yadav, RK. Goyal
- 520 9_
- $a This study was designed to assess both the quality and cost aspects of various branded and generic formulations of angiotensin receptor blockers, specifically Irbesartan, Losartan Potassium, Olmesartan Medoxomil, Telmisartan, and Valsartan. The collected samples underwent distinct quality evaluations using the methods outlined in different global Pharmacopoeias (British Pharmacopoeia/European Pharmacopoeia, Indian Pharmacopoeia and United States Pharmacopoeia). These drugs were characterized using Fourier-Transform Infrared Spectroscopy and Nuclear Magnetic Resonance techniques, while their quality and concentration were analysed using High Performance Liquid Chromatography. The release profile of the drugs was examined through dissolution testing. Additionally, a cost comparison analysis was carried out by determining the prevailing market prices of the drugs. The evaluated branded and generic angiotensin receptor blockers were found to meet the established standards for impurities, active drug content, and dissolution as set by these Pharmacopoeias, indicating their optimal quality. Notably, the generic drugs exhibited significantly lower costs compared to their branded counterparts. This study confirms that the quality of generic angiotensin receptor blockers is equivalent to that of their branded counterparts. Consequently, these findings support the practicality of utilizing generic drugs as a more economically sustainable and cost-effective approach to managing diseases, especially those of chronic nature.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Rastogi, Shruti $u Indian Pharmacopoeia Commission, Ministry of Health and Family Welfare, Government of India, Sector-23 Raj Nagar, Ghaziabad, Uttar Pradesh, 201002, India
- 700 1_
- $a Ali, Faraat $u Department of Analytical Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University, Akademika Heyrovského 1203, Hradec Králové, 500 05, Czech Republic
- 700 1_
- $a Yadav, Anuj Prakash $u Indian Pharmacopoeia Commission, Ministry of Health and Family Welfare, Government of India, Sector-23 Raj Nagar, Ghaziabad, Uttar Pradesh, 201002, India
- 700 1_
- $a Goyal, Ramesh K $u Delhi Pharmaceutical Science and Research University (DPSRU), Mehrauli-Badarpur Road, Sector-3, Pushp Vihar, New Delhi, 110017, India
- 773 0_
- $w MED00188816 $t Saudi pharmaceutical journal $x 1319-0164 $g Roč. 32, č. 3 (2024), s. 101985
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38380162 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240405 $b ABA008
- 991 __
- $a 20240412130937 $b ABA008
- 999 __
- $a ok $b bmc $g 2075987 $s 1215440
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2024 $b 32 $c 3 $d 101985 $e 20240209 $i 1319-0164 $m Saudi pharmaceutical journal $n Saudi Pharm J $x MED00188816
- LZP __
- $a Pubmed-20240405